India and China have been identified by pharmaceutical companies as the future markets that
would support drug research and development in a cost efficient manner. This has become
necessary as resources to conduct clinical studies dwindle, coupled with the fact that
pharmaceutical industries are under pressure to deliver quality medicine, on time, to the public.
Exploring and examining India and China’s potential in a stepwise fashion provides the
opportunity to dissect the good, the bad and the ugly of globalization in a comparative approach.
This paper will cover areas like ethics in the conduct of studies, good clinical practice (GCP),
economic realities, ICH influence, intellectual property security and the role of government in
global clinical trial.
Table of Contents
Abstract
The Comparative Impact of Globalization of Clinical Trials in India and China
Indian drug regulatory body versus the Chinese system
Ethics in Indian drug development versus Chinese; global clinical trial impact
Evolution of Indian ICH-GCP and the Chinese ICH-GCP processes
Intellectual property protection, government role and involvement in research
Indian and Chinese economic reality in drug development
Conclusions
Objectives and Topics
This paper examines the impact of clinical trial globalization in India and China by comparing regulatory frameworks, ethical standards, and economic factors, with the primary research objective to analyze how these emerging markets navigate the complexities of international drug development while balancing growth with participant safety.
- Comparative analysis of regulatory systems in India and China.
- Evaluation of ethical challenges in clinical trial conduct.
- Impact of ICH-GCP harmonization on local clinical practices.
- Economic implications of outsourcing research to emerging markets.
- Intellectual property protection and government involvement in pharmaceutical R&D.
Excerpt from the Book
Indian drug regulatory body versus the Chinese system
The increasing outsourcing of clinical trials to India stems from the fact that large pharmaceutical companies are pressured to deliver quality medicines to meet unmet needs in the society. In addition, dwindling research funds calls for more effective ways of doing business across the globe.
Not only that, companies are also interested in repositioning themselves to capture emerging markets as projection have shown that these markets hold great potentials for global clinical trials. The Indian pharmaceutical market capitalization was projected to grow to 2 billion US dollars as of 2010 (Chatterjee, 2008). India is now one of the emerging hubs for clinical trials as it boasts of technically competent and young workforce (More than 500,000 trained in the US and in the UK), low cost of drug development, availability of treatment naïve population, concentration of large population in urban cities, presence of major diseases, use of English as a means of communication, supportive infrastructure, population diversity, highest number of FDA-approved labs as well as friendly drug control systems (Chatterjee, 2008; Mukesh, 2009; Jankosky,Jiang,& Farwell, 2007 and China).
As companies try to take advantage of the potential gains presented by the outsourcing of clinical trials to emerging markets, their actions and inactions have impacted both positively and negatively in the evolutions of drug regulatory system, including uncovering gaps that have exposed patients to harm during trial conducts. Before now, India has demonstrated expertise in conducting research in generic medicines while hosting only 1% of US sponsored investigational new drug research (Mukesh, 2009). However, with increased outsourcing of clinical trials, and expected rise of FDA regulated drug research, India conducted 10% of FDA regulated studies back in 2010 and 15% in 2011 respectively (Jankosky,Jiang,& Farwell, 2007; Deepakmb, 2011 ). The Indian regulatory framework is repositioning itself and as well aligning its practices and organization to measure up to that of the West in order to make it competitive among emerging markets.
Summary of Chapters
Abstract: Provides a brief overview of the shift of pharmaceutical research to India and China and lists key areas of comparison such as ethics, GCP, and government regulation.
The Comparative Impact of Globalization of Clinical Trials in India and China: Introduces the economic pressures driving the outsourcing of clinical trials to emerging markets and identifies India and China as key potential hubs.
Indian drug regulatory body versus the Chinese system: Details the structural evolution of the Drug Controller General India (DCGI) and compares its approval processes and regulatory frameworks with the Chinese system.
Ethics in Indian drug development versus Chinese; global clinical trial impact: Examines the ethical challenges, including incidents of misconduct and the role of ethics committees, in both emerging markets.
Evolution of Indian ICH-GCP and the Chinese ICH-GCP processes: Analyzes the adoption of International Conference on Harmonization (ICH) guidelines and Good Clinical Practice (GCP) standards in India and China.
Intellectual property protection, government role and involvement in research: Discusses how patent laws, such as WTO-TRIPS compliance, influence R&D activities and the role of government intervention in each country.
Indian and Chinese economic reality in drug development: Evaluates the cost-efficiency, operational savings, and infrastructure growth associated with conducting clinical trials in these regions.
Conclusions: Summarizes the necessity of aligning global standards with local regulatory maturity to ensure safety and quality in international clinical research.
Keywords
Globalization, Clinical Trials, India, China, Pharmaceutical Industry, Good Clinical Practice, GCP, Ethics, Regulatory Framework, Outsourcing, Intellectual Property, WTO-TRIPS, Drug Development, Research Infrastructure, Patient Safety
Frequently Asked Questions
What is the core focus of this research paper?
The paper focuses on the comparative impact of the globalization of clinical trials in the emerging markets of India and China, specifically examining how these nations handle the regulatory and ethical demands of global pharmaceutical companies.
What are the central themes discussed in the text?
The central themes include regulatory evolution, the adoption of international ethical standards, the role of intellectual property protection, and the economic benefits that drive pharmaceutical outsourcing to these countries.
What is the primary objective of the study?
The primary objective is to analyze the "good, the bad, and the ugly" of global clinical trial outsourcing by assessing how India and China are adapting their regulatory environments to compete in the international market.
Which scientific or analytical method is used?
The paper employs a comparative analytical approach, evaluating the regulatory developments, institutional frameworks, and industry performance metrics of both India and China against global standards.
What key topics are addressed in the main body?
The main body covers the Drug Controller General India (DCGI), the Chinese State Food and Drug Administration (SFDA), ethics committee functions, ICH-GCP adoption, and patent law developments like the WTO-TRIPS agreement.
Which keywords characterize this paper?
Key terms include globalization, clinical trials, India, China, ethics, regulatory framework, outsourcing, and intellectual property.
How does India's regulatory approval process compare to international standards?
The paper highlights that while India has realigned its system to categorize trials to speed up approvals, it faces challenges with lengthy review times and a lack of formal registration for ethics committees compared to Western standards.
What role does the Chinese government play in facilitating clinical research?
The Chinese government has actively streamlined regulatory processes, introduced new drug laws in 2001, and mandated GCP certification for research sites to increase competitiveness and attract multinational investment.
What is the significance of the 2005 Indian patent law change?
The extension of WTO-TRIPS to include pharmaceutical products was intended to stimulate local R&D by providing better intellectual property protection, although some clauses regarding patentability of existing substances remain a point of contention.
How do India and China compare in terms of infrastructure for clinical trials?
Both countries boast a large, English-proficient or motivated workforce, significant populations for recruitment, and a growing number of infrastructure facilities, though they differ in their specific bureaucratic hurdles and government-led harmonization efforts.
- Quote paper
- Ginika Egesimba (Author), 2013, The Comparative Impact of Globalization of Clinical Trials in India and China, Munich, GRIN Verlag, https://www.hausarbeiten.de/document/214036
